title: The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK.
abstract: Mucormycosis is a fungal infection associated with high mortality. Until recently, the only licensed treatments were amphotericin B (AMB) formulations. Isavuconazole (ISAV) is a new mucormycosis treatment. A UK-based economic model explored treatment costs with ISAV versus liposomal AMB followed by posaconazole.
  
  
  
  As a matched case-control analysis showed similar efficacy for ISAV and AMB, a cost-minimization approach was taken. Direct costs - drug acquisition, monitoring and administration, and hospitalization costs - were estimated from the National Health Service perspective.
  
  
  
  Per-patient costs for ISAV and liposomal AMB + posaconazole were UK£26,810 and UK£41,855, respectively, with savings primarily driven by drug acquisition and hospitalization costs.
  
  
  
  ISAV may reduce costs compared with standard mucormycosis therapy.
authors.affiliation: Covance Market Access, Covance, London, UK.
authors.forename: Emma
authors.initials: E
authors.lastname: Bagshaw
authors.affiliation: Global Market Access and Health Economics, Basilea Pharmaceutica International Ltd, Basel, Switzerland.
authors.forename: Daniel
authors.initials: D
authors.lastname: Kuessner
authors.affiliation: Global Market Access and Health Economics, Basilea Pharmaceutica International Ltd, Basel, Switzerland.
authors.forename: Jan
authors.initials: J
authors.lastname: Posthumus
authors.affiliation: Global Medical Affairs, Basilea Pharmaceutica International Ltd, Basel, Switzerland.
authors.forename: Cesar
authors.initials: C
authors.lastname: Escrig
authors.affiliation: Covance Market Access, Covance, London, UK.
authors.forename: Michael
authors.initials: M
authors.lastname: Blackney
authors.affiliation: Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.
authors.forename: Sebastian Marcel
authors.initials: SM
authors.lastname: Heimann
authors.affiliation: Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.|Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, Germany.
authors.forename: Oliver Andreas
authors.initials: OA
authors.lastname: Cornely
mesh_terms: D000666:Amphotericin B / Q000191:economics / Q000627:therapeutic use; D000935:Antifungal Agents / Q000191:economics* / Q000627:therapeutic use; D016022:Case-Control Studies; D016527:Drug Costs; D006760:Hospitalization / Q000191:economics / Q000706:statistics & numerical data; D006801:Humans; D000072742:Invasive Fungal Infections / Q000188:drug therapy / Q000453:epidemiology; D018803:Models, Economic; D009091:Mucormycosis / Q000188:drug therapy*; D009570:Nitriles / Q000191:economics* / Q000627:therapeutic use; D011725:Pyridines / Q000191:economics* / Q000627:therapeutic use; D014230:Triazoles / Q000191:economics* / Q000627:therapeutic use; D006113:United Kingdom / Q000453:epidemiology
chemical_list: D000935:Antifungal Agents; D009570:Nitriles; D011725:Pyridines; D014230:Triazoles; C068538:liposomal amphotericin B; C508735:isavuconazole; C101425:posaconazole; D000666:Amphotericin B
keywords: cost; economic; healthcare; invasive fungal infection; isavuconazole; liposomal amphotericin B; mucormycosis; posaconazole